Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

NIH 5OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 22Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Rectal Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostatic Diseases 1Pancreatic Neoplasms 1Pain 1Non-squamous Non-small Cell Lung Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma 1Breast Cancer Organoids 1

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × ixabepilone × Clear all
NCT00828308 2022-03-08

Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

Brown University

Phase 2 Completed
16 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT01079793 2020-08-20

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

University of Texas Southwestern Medical Center

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00672009 2018-10-24

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

Cedars-Sinai Medical Center

Phase 2 Terminated
11 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Glandular and Epithelial, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡